Zevra Therapeutics, Inc.

Total Valuation

Zevra Therapeutics, Inc. carries a market capitalization of 733.03M, placing it among publicly traded companies globally. Its enterprise value stands at 630.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Zevra Therapeutics, Inc. currently has 59.34M shares outstanding.

Valuation Ratios

Zevra Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 14.24. The price-to-sales ratio is 6.10, and the price-to-book ratio stands at 3.91.

Enterprise Valuation

On an enterprise value basis, Zevra Therapeutics, Inc. trades at an EV/EBITDA multiple of 15.56 and an EV/FCF ratio of 16.19. The EV/Sales ratio of 4.64 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.15 provides insight into valuation relative to core operating earnings.

Financial Position

Zevra Therapeutics, Inc. maintains a current ratio of 5.17, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.69, indicating moderate leverage, while an interest coverage ratio of 7.10 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Zevra Therapeutics, Inc. posts a return on equity of 34.80 and a return on invested capital of 15.66.

Taxes

Over the trailing twelve months, Zevra Therapeutics, Inc. has paid 11.02M in income taxes, reflecting an effective tax rate of 15.91.

Stock Price Statistics

Zevra Therapeutics, Inc.'s stock has gained approximately 38.85778% over the past 52 weeks. The 50-day moving average sits at 12.06, while the 200-day moving average is 10.27.

Income Statement

Over the trailing twelve months, Zevra Therapeutics, Inc. generated 136.07M in revenue and converted that into 58.26M in net income, yielding earnings per share of 0.98. EBITDA reached 40.55M, while operating income came in at 39.07M.

Balance Sheet

Zevra Therapeutics, Inc. holds 221.57M in cash and equivalents against 1.50M in total debt, resulting in a net debt position of -145.32M. Total book value stands at 217.65M, with working capital of 202.67M providing operational flexibility.

Cash Flow

Zevra Therapeutics, Inc. produced 33.40M in operating cash flow over the past twelve months. After subtracting -775,000.00 in capital expenditures, free cash flow totaled 32.62M - equivalent to 0.56 per share.

Margins

Zevra Therapeutics, Inc. operates with a gross margin of 95.46, reflecting its pricing power and cost economics. The operating margin of 28.71 and net profit margin of 42.82 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Zevra Therapeutics, Inc.'s most recent stock split took place on December 28, 2020 with a 16:1 split ratio.

Scores

Zevra Therapeutics, Inc. posts an Altman Z-Score of 5.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.